Low-density lipoprotein cholesterol
Showing 1 - 25 of >10,000
Elevated Low-Density Lipoprotein Cholesterol Trial in Herston, Adelaide, Melbourne (SNK-396 - SAD cohort, SNK-396 - MAD Cohort)
Recruiting
- Elevated Low-Density Lipoprotein Cholesterol
- SNK-396 - SAD cohort
- SNK-396 - MAD Cohort
-
Herston, Queensland, Australia
- +2 more
Jun 6, 2023
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
- Combination for Subgroup High LDL-c Patients With Other Comorbidities
- RN0191 INJECTION
- (no location specified)
Jun 14, 2023
Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)
Not yet recruiting
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Inclisiran
- Matching Placebo for Inclisiran
- (no location specified)
May 24, 2023
OLOMAX for Blood Pressure and Low-density Lipoprotein
Recruiting
- Hypertension
- Dyslipidemias
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
-
Seoul, Korea, Republic ofSeoul St.Mary's Hospital
Dec 13, 2022
Inclisiran Among Early Users in Germany
Completed
- High Levels of Low-density Lipoprotein Cholesterol
-
Basel, SwitzerlandNovartis
May 12, 2023
Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)
Active, not recruiting
- Coronary Artery Diseasse
- fixed high potent statin therapy
- targeted LDL-C goal statin
-
Seoul, Korea, Republic ofDivision of Cardiology, Department of Internal Medicine, Yonsei
Jul 19, 2022
COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism Trial in Chongqing
Active, not recruiting
- COVID-19 Stress Syndrome
- +5 more
- Atorvastatin Calcium Tablets
-
Chongqing, Chongqing, ChinaResidential Address
May 1, 2023
Low-density Lipoprotein Cholesterol Reduction With
Recruiting
- Acute Coronary Syndrome
- Dyslipidemias
-
Banja Luka, Republic Of Srpska, Bosnia and HerzegovinaUniversity Clinical Centre of the Republic of Srpska
Oct 17, 2021
Categories and Attaining LDL-C Targets in Middle Eastern Adults
Not yet recruiting
- Atherosclerotic Cardiovascular Risk
- Low-density-lipoprotein (LDL) Cholesterol
- (no location specified)
Feb 16, 2023
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Inclisiran
- Behavioural Support
-
Sale, Cheshire, United Kingdom
- +16 more
Jan 20, 2023
Hypercholesterolemia Trial in Adelaide (Swisse Nutra+ Cholesterol Balance, Placebo)
Completed
- Hypercholesterolemia
- Swisse Nutra+ Cholesterol Balance
- Placebo
-
Adelaide, South Australia, AustraliaCSIRO Nutrition and Health Research Clinic
Mar 9, 2022
Improving Systolic BP and LDL-C Compared to Conventional
Not yet recruiting
- Hyperlipidemias
- Hypertension
- Rosuvastatin, Olmesartan Medoxomil
- (no location specified)
Jun 6, 2022
Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27
Completed
- Coronary Disease
- MK0653, ezetimibe / Duration of Treatment: 27 Weeks
- +2 more
- (no location specified)
Feb 7, 2022
Hypercholesterolemia, Atherosclerosis Trial (Ezetimibe, Placebo)
Terminated
- Hypercholesterolemia
- Atherosclerosis
- Ezetimibe
- Placebo
- (no location specified)
Feb 7, 2022
Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg
Completed
- Hyperlipidemia
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
- +2 more
-
Changsha, Hunan, China
- +2 more
Dec 2, 2021
Familial Hypercholesterolaemia Trial in Czechia (Total cholesterol (TC) level test and direct Low density lipoprotein
Recruiting
- Familial Hypercholesterolaemia
- Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test
- DNA testing
-
Brno, Czechia
- +10 more
Nov 25, 2022
Acute Aortic Syndrome, Aortopathy Trial in Nanjing, Beijing (Rosuvastatin 10mg)
Recruiting
- Acute Aortic Syndrome
- Aortopathy
- Rosuvastatin 10mg
-
Nanjing, Jiangsu, China
- +1 more
Jul 23, 2021
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome Trial in Dallas (RVX000222, Placebo)
Completed
- Dyslipidemia
- +3 more
- RVX000222
- Placebo
-
Dallas, TexasCovance Clinical Research Unit, Inc.
Nov 1, 2022
Predictor of No-reflow in Diabetic Patients
Not yet recruiting
- Acute Myocardial Infarction (AMI)
- 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
- (no location specified)
Apr 7, 2021
Serum Adropin to Testosterone and Adiponectin in Obese Men
Completed
- Obesity
- Dyslipidemias
- lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
- +3 more
-
Aswan, EgyptAswan University Hospital
Feb 14, 2022
No-Reflow Phenomenon Trial (1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol)
Not yet recruiting
- No-Reflow Phenomenon
- 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
- (no location specified)
Apr 13, 2021
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol Trial in United States (Intervention Daily Avocado)
Completed
- Intra-abdominal Fat
- +13 more
- Intervention Daily Avocado
-
Loma Linda, California
- +3 more
Jan 28, 2022
Hypercholesterolemia Trial in Worldwide (inclisiran sodium, Placebo)
Active, not recruiting
- Hypercholesterolemia
- inclisiran sodium
- Placebo
-
Lanzhou, Gansu, China
- +44 more
Feb 7, 2022
Intermittent Fasting Trial in Murray (Intermittent Fasting)
Completed
- Intermittent Fasting
- Intermittent Fasting
-
Murray, UtahIntermountain Medical Center
Jul 16, 2020